Aripiprazole Long-acting Injectable Two-injection Start to Manage Supersensitivity Psychosis: A Case Report

Dopamine supersensitivity psychosis (DSP) is characterized by treatment resistance, tardive dyskinesia, and worsening psychotic symptoms due to long-term antipsychotic use. A 52-year-old woman with treatment-resistant schizophrenia and possible DSP continued to experience persistent psychotic symptoms despite high-dose antipsychotic treatment. Through close follow-up, symptom improvement was observed following the gradual reduction of antipsychotic doses and the introduction of the aripiprazole long-acting injectable (LAI) two-injection start regimen. This approach may offer a rapid and effective strategy for stabilizing dopamine receptors in patients with DSP. This case highlights the potential role of aripiprazole LAI in DSP management and symptom improvement in complex clinical presentations.